Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Overall tumor genomic instability: an important predictor of recurrence-free survival in patients with localized clear cell renal cell carcinoma.

Correa AF, Ruth KJ, Al-Saleem T, Pei J, Dulaimi E, Kister D, Collins M, Abbosh PH, Slifker MJ, Ross E, Uzzo RG, Testa JR.

Cancer Biol Ther. 2020 May 3;21(5):424-431. doi: 10.1080/15384047.2020.1721251. Epub 2020 Mar 1.

PMID:
32116106
2.

ZBP1/DAI Drives RIPK3-Mediated Cell Death Induced by IFNs in the Absence of RIPK1.

Ingram JP, Thapa RJ, Fisher A, Tummers B, Zhang T, Yin C, Rodriguez DA, Guo H, Lane R, Williams R, Slifker MJ, Basagoudanavar SH, Rall GF, Dillon CP, Green DR, Kaiser WJ, Balachandran S.

J Immunol. 2019 Sep 1;203(5):1348-1355. doi: 10.4049/jimmunol.1900216. Epub 2019 Jul 29.

PMID:
31358656
3.

Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.

Kukuyan AM, Sementino E, Kadariya Y, Menges CW, Cheung M, Tan Y, Cai KQ, Slifker MJ, Peri S, Klein-Szanto AJ, Rauscher FJ 3rd, Testa JR.

Cancer Res. 2019 Aug 15;79(16):4113-4123. doi: 10.1158/0008-5472.CAN-18-4093. Epub 2019 May 31.

4.

Estrogen metabolism in the human lung: impact of tumorigenesis, smoke, sex and race/ethnicity.

Peng J, Meireles SI, Xu X, Smith WE, Slifker MJ, Riel SL, Zhai S, Zhang G, Ma X, Kurzer MS, Ma GX, Clapper ML.

Oncotarget. 2017 Nov 1;8(63):106778-106789. doi: 10.18632/oncotarget.22269. eCollection 2017 Dec 5.

5.

NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.

Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA.

Nat Commun. 2017 Nov 24;8(1):1772. doi: 10.1038/s41467-017-01877-7.

6.

MHC-I Genotype Restricts the Oncogenic Mutational Landscape.

Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, de Prisco N, Ideker T, Hildebrand WH, Font-Burgada J, Carter H.

Cell. 2017 Nov 30;171(6):1272-1283.e15. doi: 10.1016/j.cell.2017.09.050. Epub 2017 Oct 26.

7.

miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells.

Lulla AR, Slifker MJ, Zhou Y, Lev A, Einarson MB, Dicker DT, El-Deiry WS.

Cancer Res. 2017 Dec 15;77(24):6902-6913. doi: 10.1158/0008-5472.CAN-17-1767. Epub 2017 Oct 23.

8.

A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes.

Ariazi EA, Taylor JC, Black MA, Nicolas E, Slifker MJ, Azzam DJ, Boyd J.

Mol Cancer Res. 2017 Feb;15(2):152-164. doi: 10.1158/1541-7786.MCR-16-0283. Epub 2016 Nov 15.

9.

Lack of global epigenetic methylation defects in CBS deficient mice.

Lee HO, Wang L, Kuo YM, Gupta S, Slifker MJ, Li YS, Andrews AJ, Kruger WD.

J Inherit Metab Dis. 2017 Jan;40(1):113-120. doi: 10.1007/s10545-016-9958-5. Epub 2016 Jul 21.

10.

RIPK3 Is Largely Dispensable for RIG-I-Like Receptor- and Type I Interferon-Driven Transcriptional Responses to Influenza A Virus in Murine Fibroblasts.

Nogusa S, Slifker MJ, Ingram JP, Thapa RJ, Balachandran S.

PLoS One. 2016 Jul 8;11(7):e0158774. doi: 10.1371/journal.pone.0158774. eCollection 2016.

11.

A global profile of gene promoter methylation in treatment-naïve urothelial cancer.

Ibragimova I, Dulaimi E, Slifker MJ, Chen DY, Uzzo RG, Cairns P.

Epigenetics. 2014 May;9(5):760-73. doi: 10.4161/epi.28078. Epub 2014 Feb 12.

12.

MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.

Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, Uzzo RG, Cairns P.

Cancer Biol Ther. 2014 Mar 1;15(3):329-41. doi: 10.4161/cbt.27314. Epub 2013 Dec 18.

13.

Genome-wide promoter methylome of small renal masses.

Ibragimova I, Slifker MJ, Maradeo ME, Banumathy G, Dulaimi E, Uzzo RG, Cairns P.

PLoS One. 2013 Oct 24;8(10):e77309. doi: 10.1371/journal.pone.0077309. eCollection 2013.

14.

Germline Mutations in Mtap Cooperate with Myc to Accelerate Tumorigenesis in Mice.

Kadariya Y, Tang B, Wang L, Al-Saleem T, Hayakawa K, Slifker MJ, Kruger WD.

PLoS One. 2013 Jun 26;8(6):e67635. doi: 10.1371/journal.pone.0067635. Print 2013.

15.

Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.

Gupta S, Wang L, Anderl J, Slifker MJ, Kirk C, Kruger WD.

Hum Mutat. 2013 Aug;34(8):1085-93. doi: 10.1002/humu.22335. Epub 2013 May 13.

16.

Estrogen metabolism within the lung and its modulation by tobacco smoke.

Peng J, Xu X, Mace BE, Vanderveer LA, Workman LR, Slifker MJ, Sullivan PM, Veenstra TD, Clapper ML.

Carcinogenesis. 2013 Apr;34(4):909-15. doi: 10.1093/carcin/bgs402. Epub 2012 Dec 31.

17.

Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time.

Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, Tapia C, Kim HR, Yerrum S, Sharma CG, Nicolas E, Balagurunathan Y, Ross EA, Jordan VC.

Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18879-86. doi: 10.1073/pnas.1115188108. Epub 2011 Oct 19.

18.

NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis.

Thapa RJ, Basagoudanavar SH, Nogusa S, Irrinki K, Mallilankaraman K, Slifker MJ, Beg AA, Madesh M, Balachandran S.

Mol Cell Biol. 2011 Jul;31(14):2934-46. doi: 10.1128/MCB.05445-11. Epub 2011 May 16.

19.

The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.

Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC.

Cancer Res. 2010 Feb 1;70(3):1184-94. doi: 10.1158/0008-5472.CAN-09-3068. Epub 2010 Jan 19.

20.

Mouse models of cystathionine beta-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia.

Gupta S, Kühnisch J, Mustafa A, Lhotak S, Schlachterman A, Slifker MJ, Klein-Szanto A, High KA, Austin RC, Kruger WD.

FASEB J. 2009 Mar;23(3):883-93. doi: 10.1096/fj.08-120584. Epub 2008 Nov 5.

21.

Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.

Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR.

Clin Cancer Res. 2004 Jul 15;10(14):4645-51.

22.

Hardy-Weinberg equilibrium diagnostics.

Rogatko A, Slifker MJ, Babb JS.

Theor Popul Biol. 2002 Nov;62(3):251-7.

PMID:
12408944

Supplemental Content

Loading ...
Support Center